Abbott

JDRF appoints David E. Wheadon as executive vice president of research and advocacy

Thursday, May 9, 2013 12:04 PM

Juvenile Diabetes Research Foundation (JDRF), a global organization funding type 1 diabetes (T1D) research, has appointed David E. Wheadon, M.D., as its new executive vice president of research and advocacy.

More... »

David A. Dodd appointed president and CEO of Aeterna Zentaris

Friday, April 26, 2013 03:05 PM

Aeterna Zentaris, an oncology and endocrinology drug development company, has appointed David A. Dodd as president and CEO, succeeding Juergen Engel, PhD. Dodd has also been appointed director on the company's board of directors.

More... »

PPD appoints Jay Dixon as vice president, global quality and compliance

Tuesday, March 26, 2013 08:00 AM

Pharmaceutical Product Development (PPD), a global CRO, has appointed Jay Dixon as senior vice president, global quality and compliance. Dixon’s expertise will enhance PPD’s ability to deliver industry-leading drug development services and high-quality data across the full spectrum of the research and development life cycle.

More... »

Abbott, Janssen, Pharmacyclics to develop companion test for leukemia therapy

Friday, February 22, 2013 11:16 AM

Global healthcare company Abbott has formed a collaboration with Janssen Biotech and Pharmacyclics, a biopharmaceutical company based in Sunnyvale, Calif., to explore the benefits of Abbott's proprietary FISH (fluorescence in situ hybridization) technology for use in developing a molecular companion diagnostic test to identify patients with a genetic subtype of chronic lymphocytic leukemia (CLL), the most common form of adult leukemia.

More... »

Abbott completes separation of research-based pharmaceuticals business

Wednesday, January 2, 2013 02:09 PM

Global healthcare company Abbott Laboratories has completed the separation of its research-based pharmaceuticals business, which became AbbVie, a new independent biopharmaceutical company. AbbVie began trading independently on the New York Stock Exchange on Jan. 2, 2013, under the symbol "ABBV."

More... »

Abbott board approves separation of AbbVie

Thursday, November 29, 2012 01:46 PM

The board of directors of Illinois-based Abbott has approved the separation of its research-based pharmaceuticals business, to be known as AbbVie, and declared a special dividend distribution of all outstanding shares of AbbVie common stock.

More... »

Abbott announces phase III Hep C program details

Friday, November 16, 2012 02:25 PM

Abbott Laboratories, a global healthcare company, has released details on its phase III hepatitis C registration program following promising results from its phase IIb clinical trial, known as Aviator.

More... »

Insmed appoints Andrew Drechsler as CFO

Thursday, November 8, 2012 02:49 PM

Insmed, a biopharmaceutical company focused on inhaled therapeutics for serious lung diseases, has appointed Andrew Drechsler to the position of chief financial officer.

More... »

Seattle Genetics, Abbott expand antibody-drug conjugate collaboration

Wednesday, October 24, 2012 11:02 AM

Seattle Genetics, a Bothell, Wash.-based biotech focused on monoclonal antibody-based therapies for the treatment of cancer, has expanded its antibody-drug conjugate (ADC) collaboration with Abbott Laboratories, a global healthcare company.

More... »

10 pharmas form nonprofit TransCelerate to accelerate R&D of new medicines

Wednesday, September 19, 2012 02:46 PM

Ten biopharmaceutical companies have formed a non-profit organization, TransCelerate BioPharma, to accelerate the development of new medicines. Participants include Abbott, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Pfizer, Genentech and Sanofi.

More... »